Synairgen focuses on potentially breakthrough coronavirus treatment now at last stage of trials
The company has been developing a treatment for chronic lung disease in-house now tested for COVID-19
Company
Synairgen PLC
LON:SNG
Synairgen PLC is a UK-based respiratory company focused on drug discovery and the development of SNG001 (inhaled interferon beta) as potentially the first host-targeted, broad-spectrum antiviral treatment delivered directly into the lungs for severe viral lung infections.
149 stories · page 3 of 8
Synairgen completes recruitment of patients for home coronavirus trial
“The trial is both a test of the drug, and a test of how technology can be utilised to deliver and manage the administration"
Coronavirus: Synairgen starts final phase of treatment trials days after UK introduces new regimen
A recap on the current therapies available for COVID-19 patients
Synairgen phase III trial of potentially breakthrough coronavirus treatment now underway
“We believe this trial presents an opportunity for a significant UK scientific breakthrough and, if given the right support, our drug could rapidly assist with the global crisis," said chief executive, Richard Marsden
Archive
Proactive news headlines: Synairgen, Scancell, EQTEC, Great Western Mining, Trident Royalties ...
A glance at some of the day's highlights from the Proactive Investors newswire
Synairgen speeds up the trial of potential coronavirus treatment
“SNG0011 is one of the few potential treatments to have shown efficacy against severe viral lung infections such as COVID-19"
Archive
FTSE 100 closes end of week lower as markets lack direction
Britain's benchmark of leading shares closed down nearly 22 points at 6,529
Archive
Small Cap Movers: Pfizer’s positive vaccine news prompts stocks sell-off
A look back at some of the more interesting stories from London's junior market over the past week
Archive
Proactive news headlines: Synairgen, Alien Metals, Sensyne Health, Vast Resources …
A glance at some of the day's highlights from the Proactive Investors newswire
Synairgen says inhaled drug formulation could treat patients suffering with coronavirus and flu
Patients who were given the company's inhaled formulation of interferon beta-1a had greater odds of improvement and recovered more rapidly than those given a placebo
Archive
Small Cap Movers: ‘Ten-baggers’ Synairgen, Alien Metals keep up impressive share price runs
A look back at some of the more interesting stories from London's junior market this week
Synairgen gets house broker upgrade after impressive fundraise
"We now have the resources to be able to rapidly progress this potential breakthrough treatment
Synairgen successfully closes £80mln share sale to fund pivotal trial and manufacturing of breakthrough COVID-19 drug
The company could receive a further £7mln from an open offer of stock to investors that did not take part in the placing in which shares were sold at 175p each
Proactive news headlines: Synairgen, Westminster Group, Jersey Oil & Gas, Powerhouse Energy...
A glance at some of the day's highlights from the Proactive Investors newswire
Synairgen teams up with Clinigen to provide a managed access programme for Covid treatment
Chief executive Richard Marsden said the Synairgen team was “working tirelessly to progress SNG001 through the required clinical and regulatory channels"
Synairgen submits patent application for SNG001 treatment
The application covers the use of SNG001 to treat virus-induced exacerbations in patients suffering from COPD
Synairgen says interim readout supportive of coronavirus programme
The analysis of SNG001 revealed it was well tolerated in this older population studied and that lung antiviral responses were “significantly enhanced”
Demand for healthcare stocks similar to late 90s tech boom, says analyst
Turner Pope's Andy Thacker said there has been a boom in investor demand for firms in the biotech and health spaces since the onset of the coronavirus pandemic
Synairgen boss says SNG001 results “a clearer signal than we could have dared hope for”
On Monday, the company reported that patients who received its treatment had a 79% lower risk of developing severe disease compared to those given the placebo
Synairgen targets in-home patients for next phase of SNG001 trial
On Monday morning, the company unveiled results from a clinical trial which showed that patients that received the treatment had a 79% lower risk of developing the severe version of the disease than those taking a placebo